GeoVax Labs, Inc. (NASDAQ:GOVX) Sees Large Decline in Short Interest

GeoVax Labs, Inc. (NASDAQ:GOVX) was the target of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 610,600 shares, a decline of 12.3% from the February 28th total of 696,400 shares. Approximately 6.9% of the shares of the company are sold short. Based on an average daily volume of 678,200 shares, the days-to-cover ratio is presently 0.9 days.

GeoVax Labs Stock Down 7.6 %

NASDAQ:GOVX traded down $0.09 during trading hours on Thursday, hitting $1.09. 163,639 shares of the stock traded hands, compared to its average volume of 607,203. The company has a market cap of $10.29 million, a price-to-earnings ratio of -0.19 and a beta of 3.06. GeoVax Labs has a 1 year low of $1.03 and a 1 year high of $11.18. The stock has a 50 day moving average price of $1.60 and a 200 day moving average price of $2.09.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Thursday, March 27th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.49. The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $2.38 million. Equities analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, D. Boral Capital reiterated a “buy” rating and issued a $18.00 price objective on shares of GeoVax Labs in a research note on Friday, March 28th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, GeoVax Labs has an average rating of “Buy” and a consensus price target of $14.20.

Institutional Trading of GeoVax Labs

Several institutional investors have recently made changes to their positions in GOVX. Citadel Advisors LLC purchased a new position in GeoVax Labs in the 4th quarter worth approximately $104,000. Virtu Financial LLC purchased a new stake in GeoVax Labs during the 3rd quarter valued at approximately $97,000. Geode Capital Management LLC raised its position in shares of GeoVax Labs by 59.0% during the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after buying an additional 33,440 shares during the last quarter. Finally, Northern Trust Corp purchased a new position in shares of GeoVax Labs in the fourth quarter worth $29,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.